Showing results (21-30 of 160) with videos related to
Sort By:
Pageof 16
Yonsei Medical Journal|January 5, 2010
The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerByoung Chul Cho, Joo Hang Kim, Ross A Soo, et al.Cancer Treatment Reviews|February 26, 2018
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategiesSun Min Lim, Nicholas L Syn, Byoung Chul Cho, et al.Cancer Treatment Reviews|June 13, 2021
The promise of bispecific antibodies: Clinical applications and challengesSun Min Lim, Kyoung-Ho Pyo, Ross A Soo, et al.Journal of Thoracic Disease|January 21, 2012
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancerPei-Jye Voon, Byoung Chul Cho, Wee-Lee Yeo, et al.Therapeutic Advances in Medical Oncology|September 10, 2019
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancerJia Li Low, Robert J Walsh, Yvonne Ang, et al.Biosensors & Bioelectronics|August 3, 2015
A rapid MZI-IDA sensor system for EGFR mutation testing in non-small cell lung cancer (NSCLC)Qing Liu, Swee Yin Lim, Ross A Soo, et al.Journal of Thoracic Disease|August 18, 2020
Different treatment efficacies and side effects of cytotoxic chemotherapyLow-Jia Li, Qingyun Chong, Lingzhi Wang, et al.Lung Cancer (Amsterdam, Netherlands)|June 2, 2014
Immunotherapy in the treatment of non-small cell lung cancerRaghav Sundar, Richie Soong, Byoung-Chul Cho, et al.Respirology (Carlton, Vic.)|January 14, 2019
Somatic mutations and immune checkpoint biomarkersBrielle A Parris, Eloise Shaw, Brendan Pang, et al.Translational Lung Cancer Research|January 25, 2021
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)Bing Xia, Misako Nagasaka, Viola W Zhu, et al.Pageof 16